<?xml version="1.0" encoding="UTF-8"?>
<p>As global mass-treatment efforts continue, new vaccines are being advanced with the hope that they could become licensed and integrated into MDA or childhood vaccination programs in the 2020s. Anthelminthic vaccines targeting schistosomiasis and hookworm infection are advancing in clinical trials, while a new onchocerciasis vaccine is completing preclinical development, with the hope that these new and innovative technologies might accelerate global control or elimination [
 <xref rid="pntd.0007872.ref014" ref-type="bibr">14</xref>â€“
 <xref rid="pntd.0007872.ref017" ref-type="bibr">17</xref>]. New leishmaniasis vaccines are being developed, possibly for use in the Middle East or East Africa where the disease burden is the highest [
 <xref rid="pntd.0007872.ref018" ref-type="bibr">18</xref>], as is a new therapeutic Chagas disease vaccine to enhance efficacy of antiparasitic drug treatment [
 <xref rid="pntd.0007872.ref019" ref-type="bibr">19</xref>]. New arbovirus vaccines for dengue, Zika, and chikungunya are also in various stages of clinical testing, and at least one dengue vaccine has already been licensed [
 <xref rid="pntd.0007872.ref020" ref-type="bibr">20</xref>]. A new Ebola virus vaccine is being used to combat a large epidemic in eastern DR Congo, with more than 200,000 people vaccinated to date and preliminary assessments suggesting it is highly effective [
 <xref rid="pntd.0007872.ref021" ref-type="bibr">21</xref>]. Similarly, cholera vaccines have been stockpiled by WHO and have found use in multiple reactive settings where outbreaks are underway [
 <xref rid="pntd.0007872.ref022" ref-type="bibr">22</xref>]. Many of the vaccines that prevent or treat NTDs are only partially protective so they may not necessarily replace existing control approaches, but rather they would likely be developed and implemented as companion technologies [
 <xref rid="pntd.0007872.ref023" ref-type="bibr">23</xref>].
</p>
